Written and maintained by CASRAI Editorial Board
Last updated
The Karnofsky Performance Status (KPS) scale—introduced in 1948–1949 by medical oncologists David A. Karnofsky and Joseph H. Burchenal at Memorial Sloan Kettering Cancer Center—is the foundational clinician-rated instrument for quantifying a patient’s functional impairment, ability to work, and need for custodial or medical care. Scored in 10-point decile increments from 100% (normal health, no complaints, no evidence of disease) down to 0% (dead), KPS was the first standardized functional performance measure in clinical medicine and remains a mandatory baseline stratification variable, eligibility gatekeeper, and prognostic anchor across oncology clinical trials, hematopoietic stem cell transplantation (CIBMTR), neuro-oncology (RANO), and palliative performance scale workflows.
In contemporary adult and pediatric oncology trials, study protocols pair or crosswalk the 11-level Karnofsky Performance Status (KPS) with the 6-grade Eastern Cooperative Oncology Group (ECOG) / Zubrod Performance Status (0–5) for adults and the Lansky Play-Performance Scale (100–0) for children under 16 years of age.
What Are the 11 Decile Levels (100% Down to 0%) of the Karnofsky Performance Status (KPS) Scale?
In Karnofsky and Burchenal’s original 1949 taxonomy (The Clinical Evaluation of Chemotherapeutic Agents in Cancer), the 11 decile levels from 100% to 0% are organized into three broad functional categories (Categories A, B, and C) defined by whether the patient can work and carry on normal activity (80%–100%), cannot work but can live at home and care for most personal needs (50%–70%), or is unable to care for self and requires institutional/hospital-level care (0%–40%).
| Functional Tier (Category A / B / C) | KPS Score (%) | Official Karnofsky & Burchenal Clinical Definition |
|---|---|---|
| Category A (80%–100%): Able to carry on normal activity and to work; no special care is needed. |
100% | Normal; no complaints; no evidence of disease. |
| 90% | Able to carry on normal activity; minor signs or symptoms of disease. | |
| 80% | Normal activity with effort; some signs or symptoms of disease. | |
| Category B (50%–70%): Unable to work; able to live at home and care for most personal needs; varying amount of assistance is needed. |
70% | Cares for self; unable to carry on normal activity or to do active work. |
| 60% | Requires occasional assistance, but is able to care for most of their personal needs. | |
| 50% | Requires considerable assistance and frequent medical care. | |
| Category C (0%–40%): Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly. |
40% | Disabled; requires special care and assistance. |
| 30% | Severely disabled; hospital admission is indicated although death not imminent. | |
| 20% | Very sick; hospital admission necessary; active supportive treatment necessary. | |
| 10% | Moribund; fatal processes progressing rapidly. | |
| 0% | Dead. |
Australia-Modified Karnofsky Performance Status (AKPS) for Outpatient Palliative Care
Because the original 1949 KPS definitions for 30% and 20% explicitly reference “hospital admission indicated/necessary,” they create scoring ambiguity for contemporary home-hospice and community palliative care patients who are bedbound (KPS ≤ 30%) but cared for at home rather than in an acute hospital. To resolve this, Abernethy and colleagues (2005) validated the Australia-Modified Karnofsky Performance Status (AKPS), which retains the exact 100%–0% decile structure of KPS down to 40% (“In bed more than 50% of the time”) and replaces the hospitalization wording at 30%, 20%, and 10% with setting-neutral functional descriptors: AKPS 30% = “Almost completely bedfast,” AKPS 20% = “Totally bedfast and requiring extensive nursing care by professionals and/or family,” and AKPS 10% = “Comatose or barely rousable.”
What Are the 6 Grades (0 to 5) of the ECOG / Zubrod Performance Status Scale, and How Do KPS and ECOG Crosswalk?
To simplify clinician scoring and improve inter-observer concordance in multi-center cooperative group trials, Charles G. Zubrod (1960) and the Eastern Cooperative Oncology Group (Oken et al., 1982) compressed functional assessment into a 6-point ordinal scale running from Grade 0 (fully active) to Grade 5 (dead)—also adopted by the World Health Organization (WHO Performance Status).
In oncology trial design, electronic clinical outcome assessment (eCOA) systems, and PCORnet Common Data Model / OMOP data harmonization, the standard ECOG-to-KPS crosswalk (validated by Buccheri et al., 1996, and endorsed by ECOG-ACRIN and NRG Oncology) maps two KPS deciles to each active ECOG grade:
| ECOG / Zubrod Grade | Official ECOG-ACRIN Definition (Oken et al., 1982) | Equivalent KPS Score (%) | Typical Oncology Trial Eligibility Status |
|---|---|---|---|
| ECOG 0 | Fully active, able to carry on all pre-disease performance without restriction. | 90% – 100% | Eligible for all Phase I–III systemic therapy trials |
| ECOG 1 | Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature (e.g., light house work, office work). | 70% – 80% | Eligible for all standard Phase I–III oncology trials |
| ECOG 2 | Ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours. | 50% – 60% | Borderline threshold: many trials require KPS ≥ 70% (ECOG 0–1) or KPS ≥ 60% (ECOG 0–2) |
| ECOG 3 | Capable of only limited self-care; confined to bed or chair more than 50% of waking hours. | 30% – 40% | Generally excluded from cytotoxic chemotherapy trials; eligible for supportive/palliative trials |
| ECOG 4 | Completely disabled; cannot carry on any self-care; totally confined to bed or chair. | 10% – 20% | Excluded from interventional systemic therapy; hospice/comfort care indicated |
| ECOG 5 | Dead. | 0% | Mortality endpoint |
Notice the critical clinical boundary between ECOG 2 (KPS 50%–60%) and ECOG 3 (KPS 30%–40%): whether the patient spends more than 50% of waking hours out of bed/chair (ECOG 2) versus confined to bed or chair (ECOG 3). In neuro-oncology (such as glioblastoma trials using Response Assessment in Neuro-Oncology [RANO] criteria) and allogeneic hematopoietic cell transplantation registries (CIBMTR), protocols still prefer the 11-level KPS over ECOG because distinguishing KPS 70% from KPS 80% and KPS 60% from KPS 50% carries significant independent prognostic weight for overall survival and treatment-related mortality.
How Is the Lansky Play-Performance Scale (100–0) Used for Pediatric Oncology Patients Under Age 16?
Because infants, toddlers, and school-age children do not hold employment and rely on parents for developmentally normal self-care, adult KPS anchors (“unable to work,” “cares for self”) cannot be validly applied to pediatric patients. To provide a parallel 11-decile (100 to 0) functional measure for children, Shirley B. Lansky and colleagues (1987) developed the parent- and clinician-rated Lansky Play-Performance Scale (LPPS) for pediatric oncology patients aged 1 to 16 years (while patients ≥ 16 years are scored using the adult Karnofsky scale):
- Mild to No Restriction (Lansky 80–100):
- 100: Fully active, normal.
- 90: Minor restrictions in physically strenuous activity.
- 80: Active, but gets tired more quickly.
- Moderate Restriction (Lansky 50–70):
- 70: Both greater restriction of and less time spent in play activity.
- 60: Up and around, but minimal active play; keeps busy with quieter activities.
- 50: Gets dressed, but lies around much of the day; no active play, able to participate in all quiet play and activities.
- Severe Restriction (Lansky 0–40):
- 40: Mostly in bed; participates in quiet activities.
- 30: In bed; needs assistance even for quiet play.
- 20: Often sleeping; play entirely limited to very passive activities.
- 10: No play; does not get out of bed.
- 0: Unresponsive / Dead.
In Children’s Oncology Group (COG) and CIBMTR clinical trials, a Lansky score interacts seamlessly with the adult Karnofsky score on case report forms (e.g., inclusion criterion stated as “Karnofsky ≥ 70% for patients ≥ 16 years of age, or Lansky ≥ 70 for patients < 16 years of age”), and can be transmitted alongside ePRO in clinical trials and HL7 FHIR Observation records using LOINC code 89243-0 (Karnofsky Performance Status score).
Frequently Asked Questions
What are the 11 decile levels (100% down to 0%) of the Karnofsky Performance Status (KPS) scale?
The Karnofsky Performance Status (KPS) scale grades functional capacity in 10% increments across three tiers: Category A (100% normal; 90% minor symptoms; 80% normal activity with effort), Category B (70% cares for self but unable to work; 60% requires occasional assistance; 50% requires considerable assistance and frequent medical care), and Category C (40% disabled; 30% severely disabled; 20% very sick requiring active supportive care; 10% moribund; 0% dead).
What are the 6 grades (0 to 5) of the ECOG / Zubrod Performance Status scale, and how do KPS and ECOG crosswalk?
The ECOG/Zubrod scale runs from Grade 0 to Grade 5 and crosswalks to KPS as follows: ECOG 0 (fully active) equals KPS 90%–100%; ECOG 1 (restricted in strenuous activity but able to do light work) equals KPS 70%–80%; ECOG 2 (ambulatory, capable of all self-care, up >50% of waking hours, unable to work) equals KPS 50%–60%; ECOG 3 (limited self-care, in bed/chair >50% of waking hours) equals KPS 30%–40%; ECOG 4 (completely disabled, 100% bed/chair-bound) equals KPS 10%–20%; and ECOG 5 (dead) equals KPS 0%.
How is the Lansky Play-Performance Scale (100–0) used for pediatric oncology patients under age 16?
Developed by Lansky et al. (1987) for children aged 1 to 16 years, the Lansky Play-Performance Scale replaces adult work and self-care criteria with age-appropriate active and quiet play milestones on an identical 100-to-0 decile scale (where 100 is fully active, 70 is greater restriction of active play, 50 is lying around much of the day but participating in quiet play, and 10 is no play and bedbound), allowing direct pooling with adult KPS scores in oncology and stem cell transplant trials.
